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ABSTRACT
Cancer stem cells (CSCs) represent a small subset of tumor cells which have the ability to self-
renew and generate the diverse cells that comprise the tumor bulk. They are responsible for
local tumor recurrence and distant metastasis. However, they are resistant to conventional
radiotherapy and chemotherapy. Novel immunotherapeutic strategies that specifically target
CSCs may improve the efficacy of cancer therapy. To immunologically target CSC phenotypes,
innate immune responses to CSCs have been reported using Natural killer cells and cd T cells.
To target CSC specifically, in vitro CSC-primed T cells have been successfully generated and
shown targeting of CSCs in vivo after adoptive transfer. Recently, CSC-based dendritic cell vac-
cine has demonstrated significant induction of anti-CSC immunity both in vivo in immunocom-
petent hosts and in vitro as evident by CSC reactivity of CSC vaccine-primed antibodies and T
cells. In addition, identification of specific antigens or genetic alterations in CSCs may provide
more specific targets for immunotherapy. ALDH, CD44, CD133, and HER2 have served as
markers to isolate CSCs from a number of tumor types in animal models and human tumors.
They might serve as useful targets for CSC immunotherapy. Finally, since CSCs are regulated by
interactions with the CSC niche, these interactions may serve as additional targets for CSC
immunotherapy. Targeting the tumor microenvironment, such as interrupting the immune cell,
for example, myeloid-derived suppressor cells, and cytokines, for example, IL-6 and IL-8, as well
as the immune checkpoint (PD1/PDL1, etc.) may provide additional novel strategies to enhance
the immunological targeting of CSCs. STEM CELLS 2015;33:2085—2092
INTRODUCTION
Cancer stem cells (CSCs) are defined as malig-
nant cancer cells that retain the ability to self-
renew and differentiate generating nontumori-
genic cancer cells that form a tumor mass [1].
CSCs are believed to play important roles in
tumor initiation, relapse, metastasis, and resist-
ance to traditional therapies [2]. These proper-
ties highlight the importance of developing
therapeutic strategies to target the CSC popula-
tion. Major conceptual and technical advances
in immunology over the past 25 years have led
to a new understanding of cellular and molecu-
lar interactions between the immune system
and tumor cells. In parallel, recent advances in
tumor immunotherapy have provided powerful
new therapeutic approaches that have pro-
duced durable clinical responses with limited
toxicities in a small subset of patients [3].
Although it is currently not known what
accounts for these durable remissions receiving
immunotherapy, the possibility that this may be
related to the ability of these therapies to tar-
get CSCs warrants further exploration. If this is
demonstrated, then immunologic strategies spe-
cifically designed to target CSCs may increase
the proportion of patients experiencing these
durable remissions. Since CSCs drive tumor pro-
gression and metastasis, long-term benefit of
cancer therapies involving conventional
approaches such as surgery, chemotherapy,
and/or radiation therapy may depend on their
ability to effectively target CSCs.
CSCS ARE RESISTANT TO CONVENTIONAL
THERAPEUTIC AGENTS
Despite advances in radiation therapy and
chemotherapy, the prognosis of patients with
advanced malignant tumors remains poor. Inef-
fective targeting of CSCs has been suggested
as one reason for current treatment failure [4].
CSCs have been documented to be resistant to
various chemotherapeutic agents and radio-
therapy [5–7]. The resistance of CSCs to chem-
otherapy may involve increased expression of
drug efflux pumps, more efficient DNA repair
[5, 8], and interactions of CSCs with their
microenvironment [9, 10]. In light of CSC
resistance to conventional therapeutic agents,
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development of alternative/novel therapeutic strategies that
can specifically and effectively target CSCs is needed to
enhance the efficacy of other therapeutic agents (Fig. 1).
IMMUNOLOGICAL TARGETING OF CSC PHENOTYPES
There are a number of theoretical reasons which provide a
rationale for developing immune approaches to target CSCs. It
is clear that CSCs and their more differentiated progeny display
distinct gene expression profiles and therefore express different
antigens. Immunologic approaches directed against whole
tumors are largely biased toward more differentiated tumor
cells which form the bulk of the tumor and which express
“differentiation” antigens. This suggests that effective immune
targeting of CSC may require the specific targeting of this cell
population. In addition, within a tumor, CSCs may themselves
exhibit heterogeneity resulting from both genetic and epige-
netic regulation associated with tumor progression and metas-
tasis. For instance, we [11] have shown that breast CSCs
maintain that plasticity to transition between mesenchymal
(EMT) and epithelia (MET) states in a process regulated by the
tumor microenvironment. The ability of immunotherapies to
target multiple antigens makes these approaches well suited to
the targeting of these heterogenous CSC populations.
Innate Immune Response to CSCs
Natural killer (NK) cells are major effector cells for innate
immunity, making them suitable candidates for immunother-
apy of both hematologic and solid tumors [12, 13]. However,
the role of NK cells in anti-CSC immune surveillance remains
controversial. Wu et al. investigated the immunogenicity of
CD1331 brain tumor stem cells (BTSCs). Their data revealed
that the majority of CD1331 cells do not express detectable
MHC I or NK cell activating ligands, which may render them
resistant to adaptive and innate immune surveillance [14].
Wang et al. also reported that MICA and MICB (MHC class I-
related chain A and B), two ligands for the stimulatory NK cell
receptor NKG2D, are downregulated due to aberrant expres-
sion of oncogenic miR-20a in human breast CSCs, which
resulted in immune escape of these CSCs from NK cell killing
[15]. In contrast, Castriconi et al. reported that glioma stem
cells (GSCs) express various ligands of NK cell activation recep-
tors that trigger optimal NK cell cytotoxicity. They found that
GSCs are highly susceptible to lysis mediated by both alloge-
neic and autologous IL-2 (or IL-15)-activated NK cells [16].
Tseng et al. also showed that primary oral squamous (OS) car-
cinoma stem cells are significantly more susceptible to NK
cell-mediated cytotoxicity than their differentiated counter-
parts [17]. Tallerico et al. analyzed the NK cell recognition of
colorectal adenocarcinoma CSCs. They demonstrated that allo-
geneic NK cells can recognize and kill these CSCs but the non-
CSC counterpart is less susceptible to NK cells. Compared
with the non-CSCs, these colorectal CSCs express higher levels
of ligands for the natural cytotoxicity receptors which medi-
ates NK cell killing and lower levels of MHC class I [18].
Unconventional cd T cells represent another group of
innate immune effector cells, which constitute 1%–5% of cir-
culating lymphocytes and are of the Vc9Vd2 phenotype.
Immunotherapy with cd T cells is of substantial interest based
on their potent non-HLA-restricted cytotoxicity against differ-
ent tumor entities and their capacity to recognize and present
antigens to ab T cells [19, 20]. cd T cells primarily target iso-
pentenyl pyrophosphate, an intermediate of the mevalonate
pathway for isoprenoid biosynthesis in eukaryotic cells [21,
22]. Nishio et al. showed that Vc9Vd2 T cells mediate cytolysis
of sphere-forming neuroblastoma cells sensitized with zoledro-
nate [23]. Todaro et al. also reported that Vc9Vd2 T cells are
induced to proliferate, secrete TNF-a and IFN-c, and produce
the cytotoxic and apoptotic molecules TRAIL and granzymes
after exposure to zoledronate-sensitized human colon CSCs
[24]. In a clinical study, activated Vc9Vd2 T cells in combina-
tion with zoledronate show increased CD69 expression, indi-
cating an activated phenotype. These Vc9Vd2 T cells displayed
upregulated expression of peripheral tissue-homing chemo-
kine receptors, CCR5 and CXCR3. In contrast, there was a
decrease in expression of the lymphoid-homing receptors,
CCR7 and CXCR5 [23]. These Vc9Vd2 T cells were cytotoxic in
vitro, and adoptively transferred Vc9Vd2 T cells trafficked pre-
dominantly to the lung, liver, and spleen as well as to the
metastatic tumor sites outside these organs [25]. These results
indicate that in vitro expansion of autologous cd T cells in
combination with other antitumor agents may benefit cancer
treatment via CSC destruction. Further studies are needed to
confirm direct targeting of CSCs by cd T cells. There is a pau-
city of clinical studies involving the use of nonspecific killer
cells in the adoptive immunotherapy of solid tumors that
have examined effects on CSCs.
In Vitro CSC-Primed T Cells Specifically Target CSCs In
Vivo
CD81 T cells undergo proliferation and differentiate into cyto-
toxic T lymphocytes (CTLs) in the presence of appropriate
stimulation [26]. Activated CTLs can migrate to peripheral tis-
sues where they exert two main effector functions: direct
contact-mediated cytotoxicity and secretion of effector cyto-
kines, such as IFN-c and TNF-a. Another essential function of
activated CD81 T cells is the acquisition of memory. Memory
CD81 T cells can be maintained for long periods of time with-
out antigenic stimulation and potentiate a more potent and
faster immune response of the host upon cancer relapse or
development of metastasis [27]. CD41 T helper cells also play
a critical role in the development of effective antitumor
immunity by increasing clonal expansion of CTL at the tumor
Figure 1. The inability to target cancer stem cells represents a
significant factor contributing to current treatment failure. Abbre-
viation: CSC, cancer stem cell.
2086 Targeting Cancer Stem Cells Using Immunologic Approaches
VC AlphaMed Press 2015 STEM CELLS
site, promoting the generation and maintenance of memory
CTLs, preventing activation-induced cell death, and functioning
as antigen presenting cells (APCs) for CTLs [28].
CSC-specific CD81 T cells were generated from human
acute myeloid leukemia (AML) stem cells in 1999 by Bonnet
et al., and were observed to mediate tumor regression after
injection into NOD/SCID mice [29]. Brown et al. isolated
CD1331 BTSCs, and demonstrated that these BTSCs are sus-
ceptible to perforin-dependent CTL-mediated cytolysis [30]. To
assess whether the protein processing machinery is suffi-
ciently intact for the BTSCs population to process and present
antigen for CD81 CTL recognition, the authors engineered gli-
oma tumor sphere (TSs) to endogenously express the cyto-
megalovirus (CMV) pp65 antigen by reconstructed pp65-
lentiviral transduction. They found that CMV-specific CTLs
mediate the CMV-transducted glioma TSs cytotoxicity. When
CMV pp65-expressing TSs and pp65-specific CTLs were coin-
jected into NOD/SCID mice, the pp65 antigen-positive tumor
cells were ablated, while pp652 tumor cells were resistant to
the pp65-specific CTL and efficiently engrafted. This result
indicated that direct recognition of antigen by CTLs is
required to eliminate tumor initiation [30]. In another study,
Visus and colleagues generated CSC-specific CD81 T cells using
antigenic peptide from ALDH1A1. The transfer of ALDH1A1-
specific CD81 T cells eliminated ALDH1A1bright CSCs from
squamous cell carcinoma of the head and neck, inhibited
tumor growth and metastases, and prolonged survival of
xenograft-bearing immunodeficient mice [31, 32]. Together,
these studies suggest that CSC-specific T cells can be gener-
ated in vitro for subsequent adoptive transfer into tumor-
bearing hosts to target CSCs and eradicate tumors in vivo. In
addition, these studies have demonstrated that CSCs are sen-
sitive to T-cell-mediated killing. One problem with targeting
CSCs with CSC-specific T cells in an adoptive immunotherapy
approach is the immune escape of tumors with antigen loss.
In the next section, we describe a method of generating CSC-
specific T- and B-cell responses in vivo using a vaccine
approach and how to mitigate against antigen loss variants.
Interestingly, CSCs seem to be able to evolve strategies to
escape T-cell attack. Recently Volonte et al. reported that
CSCs derived from colorectal cancer show weak immunogenic-
ity compared with non-CSC counterparts. This feature may
correlate with the expression of high levels of IL-4 by the
CSCs because neutralization of CSC-associated IL-4 can rescue
the proliferative activity of T lymphocytes [33]. Based on the
results in this study, new immunotherapy protocols to target
CSCs might involve blocking inhibitory activity of immunomo-
dulatory molecules as well as activating T cell by CSC specific
or associated antigens.
CSC-Based Vaccines Target CSCs in Immunocompetent
Hosts
The use of professional antigen presenting cells, such as den-
dritic cells (DCs), to initiate tumor-specific T-cell responses
represents a promising strategy for cancer vaccination
approaches. Glioblastoma-derived CSCs express MHC I [34].
After coculturing human immature, autologous DCs with irra-
diated BTSCs, the CSC-primed mature DCs expressed costimu-
latory molecules CD80, CD86, and CD40, and stimulated
significant Th1 (IFN-c) response in vitro [34]. These studies
demonstrate that CSCs may be antigenic and can be used to
develop cell-specific vaccines. The efficacy of a tumor-specific
vaccine in vivo is dependent upon both cellular and humoral
host immunity. However, to date most CSC studies have been
performed with human tumor-derived CSCs in NOD/SCID mice
[29]. Due to the lack of cellular and humoral immunity, these
immunocompromised mice are not suitable for assessing the
efficacy of CSC vaccines. The lack of an intact host immune
system prevents evaluation of multiple interactions that occur
such as epitope spreading, antigen cross-presentation, and
immune evasion mechanisms such as T regulatory cells or
myeloid-derived suppressor cells; to name a few.
Based on this consideration, our group assessed the
effects of CSC-DC vaccine in various syngeneic immunocompe-
tent mouse tumor models, and demonstrated that CSC-DC
vaccination significantly prevents lung metastasis of mela-
noma cells and inhibits tumor growth of squamous carcinoma
compared to immunization with bulk tumor cells [35]. In this
study, the tumorigenicity of murine aldehyde dehydrogenase
(ALDH)1/high CSCs were demonstrated in two histologically dif-
ferent tumors (D5 melanoma and SCC7 squamous cell carci-
noma) from two genetically distinct immunocompetent hosts
(B6 and C3H mice) [35]. We used CSCs selected by virtue of
their expression of the CSC marker, ALDH as an antigen
source to prime DCs, and evaluated the protective effects of
CSC-primed DC vaccines in mouse tumor challenge models
[35]. This study demonstrated that CSC-primed DC vaccination
was significantly more effective at preventing lung metastasis
in the D5 model and subcutaneous tumor growth in the SCC7
model compared with control mice given DCs pulsed with
unsorted heterogeneous tumor cells or ALDH2/low non-CSCs.
Systemic anti-CSC immunity was associated with CSC-specific
IgG and CSC-specific CTLs present in the peripheral blood of
CSC-DC vaccinated hosts. These data indicate that enriched
CSCs are immunogenic and more effective as an antigen
source than unselected tumor cells or non-CSCs in inducing
antitumor immunity against CSC epitopes [35]. Consistent
with these observations, Phuc et al. reported that breast CSC-
DC vaccine could migrate to the spleen, activate CD81 and
CD451 T cells, and induce CTL antitumor responses [36]. Cur-
rently, we hypothesize that CSCs may have multiple epitopes
that are distinct from non-CSCs and which can be targeted by
T or B cells. Work is currently underway to identify these anti-
gens. The use of tumor lysates of CSCs as a source of antigen
would potentially allow targeting multiple antigens simultane-
ously; and would be less susceptible to antigen loss as a
means of tumor escape.
A number of studies have suggested that tumor vaccines
have their greatest efficacy in the setting of micrometastatic
disease. Due to the low percentage of CSCs within established
tumor masses, CSC-targeted DC vaccines may have minimal
effect on tumor size. We postulate that CSC-DC may have maxi-
mum utility when deployed in an adjuvant setting after surgical
removal of the bulk tumor mass to target microscopic residual
CSCs or as combinatorial therapy with radiation and/or chemo-
therapy in the therapy of established macroscopic tumors.
Using an established murine tumor model, we found that treat-
ment of microscopic tumor by CSC-DC was more efficacious
that DCs pulsed with non-CSCs (Lin et al., in press, OncoImmu-
nology, 2015). Furthermore, in the established macroscopic
tumor setting, the combination of radiation therapy (RT) plus
CSC-DC vaccine was more effective than RT alone or CSC-DC
Pan, Li, Liu et al. 2087
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alone in reducing tumor growth and improving survival (Lin
et al., in press, OncoImmunology, 2015). In assessing the per-
centage of CSC in the treated primary tumors, RT alone
resulted in an increased percent of CSC whereas CSC-DC
resulted in significant decrease in the percent of CSC (Lin et al.,
in press, OncoImmunology, 2015). Mice treated with the com-
bination of RT and CSC-DC vaccine had significantly fewer spon-
taneous lung metastases compared with other control groups
indicating the relationship between the ability to target CSC
and a reduction in spontaneous metastatic disease (Lin et al.,
in press, OncoImmunology, 2015).
IMMUNOLOGICAL TARGETING OF CSC ANTIGENS
Cancer immunotherapy is based on the ability of the immune
system to recognize cancer cells and to affect their growth
and expansion. This suggests that proteins express on CSCs
may provide targets for CSC immunotherapies. CSCs express
various markers, including ALDH, CD44, CD133, and HER2, at
levels substantially different from the bulk tumor cell popula-
tion. These markers have proven useful for identifying and
isolating CSCs. These CSC markers may provide specific targets
for CSC immunotherapies.
ALDH
ALDH is responsible for the oxidation of aldehydes to carbox-
ylic acids to prevent cells from oxidative insult and facilitate
their survival. Increased ALDH activity has been found in CSCs
of various tumor types, such as bladder, breast, colon, gastric,
head and neck, lung, pancreatic, prostate as well as hemato-
poietic and neural stem/progenitor cells [37–46]. In addition,
ALDH-mediated detoxification of toxic aldehyde intermediates
produced in cancer cells treated with certain chemotherapy
agents has been proposed to confer drug-resistant properties
to ALDHhigh tumor cells [45]. Dylla et al. found that using
short hairpin RNA against ALDH1 sensitized human colorectal
CSCs to cyclophosphamide [47]. Raha et al. defined a require-
ment for ALDH in the maintenance of a drug-tolerant subpo-
pulation of cancer cells that share some properties with CSCs.
ALDH protects these CSCs from the potentially toxic effects of
elevated levels of reactive oxygen species in the cells [48].
Immunological targeting of ALDH activity in vitro and in
vivo has been reported by several groups. Visus et al. gener-
ated ALDH-specific CD81 T cells that recognized and eliminated
the ALDHhigh tumor cells in human carcinomas [32]. In this
work, ALDH-specific CD81 T cells were induced/expanded by in
vitro stimulation of human CD81 T cells with ALDH peptide-
pulsed autologous DCs. The percentages of ALDHhigh cells were
decreased by 60%–89% resulting from ALDH-specific CD81 T-
cell-mediated cytotoxicity in vitro. In preclinical models using
human tumor xenografts in immunodeficient mice, ALDH-
specific CD81 T cells inhibited xenograft growth and metasta-
ses, and prolonged survival after adoptive transfer. These
results clearly demonstrated that ALDH can serve as potential
target for T-cell-based immunotherapy to eliminate CSCs [32].
In addition to ALDH being a CSC marker, there is increas-
ing evidence that it plays an important functional role in
these cells. For example, Wang et al. demonstrated that disul-
firam (DSF) an irreversible inhibitor of ALDH activity blocked
the formation of radiation-induced breast CSCs [49]. In their
work, irradiation-induced stemness correlates with increased
spontaneous lung metastasis in syngeneic mouse mammary
tumor models. However, irradiation-induced stemness was
blocked by targeting ALDH activity with DSF. Treatment of
mice with radiation and DSF significantly inhibited mammary
primary tumor growth and spontaneous lung metastasis,
which was associated with decreased CSCs [49]. The demon-
stration of an important role of ALDH in CSC function pro-
vides an additional rationale for using it as a target for
immunotherapy since it might reduce the likelihood of
immune escape through downregulated expression.
CD44
Cell surface CD44, a highly glycosylated type-1 transmem-
brane p-glycoprotein (90 kDa), is among the most widely
used CSC markers [50]. CD44 is present in multiple species
generated by alternative splicing. Differently spliced variants
include the V6 isoform in colon cancer CSCs [50] and the
standard isoform in breast CSCs [51]. CD44 is involved in mul-
tiple signaling functions, for example, cell proliferation, apo-
ptosis, survival, migration, and differentiation [52]. Moreover,
a recent study reveals that the CD44 protein plays an impor-
tant role in a number of CSC functions including self-renewal,
niche preparation, epithelial-mesenchymal transition, and
resistance to apoptosis [53].
Considering that CD44 has its functional roles and is a
marker on CSCs, targeting CD44 with immunological
approaches represents a promising strategy to eliminate CSCs.
In 1993, Seiter et al. first reported that monoclonal antibody
1.1ASML against a splice variant of CD44 (CD44v) retarded
growth of lymph node and lung metastases from pancreatic
adenocarcinoma in rats [54]. Since then, anti-CD44 antibodies
have been shown to promote terminal differentiation of AML
blasts [55], inhibit growth of murine mammary carcinoma
cells and human colon carcinoma cells and induce apoptosis
[56], and decrease human melanoma metastasis and increase
animal survival in SCID mice [57]. Given these results, recently
several anti-CD44 antibodies have been developed and used
in anti-CSC approach [58–60]. Jin et al. used the anti-CD44
monoclonal antibody H90 to selectively eradicate AML CSCs in
NOD/SCID mice [58, 59]. They found that H90 blocked leuke-
mic stem cells trafficking to their supportive microenviron-
ment and altered stem cell fate [58]. Young et al. also
described that H460-16-2, a humanized anti-CD44 monoclonal
antibody, is able to reduce the growth of BxPC3 pancreatic
cancer xenografts by 80%. In addition, it has been demon-
strated that in AML xenografts H460-16-2 binds to
CD341CD382 CSCs increasing mouse survival. Clinical trials
using this antibody are planned [60].
CD133
Human CD133 (human prominin-1) is expressed on CSCs in a
number of solid tumors [61, 62]. Recent studies have shown
that the CD1331 subpopulation displays resistance to chemo-
therapy and radiotherapy, and high CD133 expression is a
marker of poor prognosis [62]. Several monoclonal antibodies
to CD133 have been generated [63, 64]. Our group recently
generated an anti-CD3/anti-CD133 bispecific antibody (BsAb)
and bound it to the cytokine-induced killer (CIK) cells as effec-
tor cells (BsAb-CIK) to target CD133high CSCs. We found that
killing of CD133high pancreatic (SW1990) and hepatic (Hep3B)
cancer cells by the BsAb-CIK cells was significantly higher than
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the killing by the parental CIK or by CIK cells bound with anti-
CD3 (CD3-CIK) without CD133 targeting. In nude mice, the
BsAb-CIK cells inhibited CD133high tumor growth significantly
more than that by CIK or CD3-CIK cells, or BsAb alone. Mech-
anistically, treatment with the BsAb-CIK cells significantly
downregulated the expression of S100P and IL-18bp, but
upregulated STAT1. These findings suggest a novel immuno-
therapy for patients with cancer containing CD133high CSCs
involving selective targeting of this cell population [65].
HER2
Human epidermal growth factor receptor-2 (HER2) is over-
expressed in several human cancers of epithelial origin where
it plays an essential role in tumor development [65–67]. It has
been shown that over-expression of HER2 in breast cancer is
often associated with an aggressive course characterized by
increased disease recurrence and a poor prognosis. Specifically,
we have shown that the level of ALDH in HER21 breast cancer
is much higher than that in HER22 breast cancers. HER2 regu-
lates the mammary stem/progenitor cell population, driving
tumorigenesis, invasion, and HER2-associated radioresistance of
breast CSCs [6, 67, 68]. We have shown that in HER21 breast
cancers, HER2 regulates CSC self-renewal [68] and that this is
mediated by a pathway involving Akt and B Catenin [69] and
have suggested that the ability of HER2 targeting agents to
eliminate CSC may contribute to their remarkable clinical effi-
cacy. In addition, to playing a role in HER21 breast cancers we
recently showed [67, 70] that in luminal breast cancers that
are considered HER2 negative, HER2 is selectively expressed in
the ALDHhigh CSC population. Fluorescence-activated cell sorting
analysis of ALDHhigh versus ALDHlow cells showed enrichment
for HER2 expression in ALDHhigh cells. In MCF7 and ZR75-1
human breast cancer luminal cell lines, the level of HER2
expression was considerably lower than in the HER2-amplified
cell lines. However, in these cells, HER2 expression was
increased two- to threefold in ALDHhigh cells (HER21ALDHhigh)
as compared to ALDHlow cells (HER22ALDHlow). We have char-
acterized the stem cell nature of the HER21ALDHhigh cell [71].
We have proposed that HER2 expression in luminal CSCs in the
absence of HER2 gene amplification may account for the sur-
prising finding that the benefit of adjuvant trastuzumab may
extend to patients whose tumors do not display HER2 gene
amplification [71, 72].
In addition to the use of HER2 blocking antibodies, other
immunologic approaches have been used to target HER2
expressing cells. Sen et al. reported that activated T cells armed
with anti-CD3 3 anti-HER2 bispecific antibody (HER2Bi) medi-
ate high levels of specific cytotoxicity directed at both low and
high HER2-expressing breast cancer cell lines [73]. Intravenous
infusions of HER2Bi-armed T cells inhibited the growth of
established HER21 PC-3 tumors in SCID/Beige mice and pre-
vented tumor development in coinjection WINN assays [74,
75]. Arming T cells with HER2Bi converts every T cell into a
non-MHC restricted HER2-specific CTL [73]. In a phase I clinical
trial led by Lum et al. with infusion of anti-CD3 3 anti-HER2
bispecific antibody armed T cells involving 23 HER2 negative
(0–21 IHC) metastatic breast cancer patients, the median OS
for the HER2 negative women was 25.9 months, considerably
longer than expected from historic controls (personal communi-
cation with Dr. LG Lum). Apparently, HER2Bi armed T cells,
while intended to target HER2, seem to benefit patients that
are HER2-negative by classic criteria including lack of HER2
gene amplification as determined by fluorescence in situ
hybridization. Our finding of selective HER2 expression in CSCs
in these breast cancers classified as “HER2-negative” may pro-
vide a biological explanation for these clinical findings. How-
ever, the potential of infused HER2Bi armed T cells to
specifically induce immune responses against breast CSCs
remains untested.
IMMUNOTHERAPEUTIC TARGETING OF THE CSC NICHE
CSCs reside in a niche within the tumor, which contributes to
the self-renewal and differentiation of these cells. Growth fac-
tors, cytokines, and diverse stromal cells, such as mesenchy-
mal stem cells and immune cells in the cellular
microenvironment, are essential for cell nutrition, intercellular
communication, signal transduction, and cell fate [76]. For
example, Lu et al. [77] recently demonstrated that tumor-
associated monocytes and macrophages create a niche
through juxtacrine signaling of CSCs. These studies suggest
that components in CSC niche may provide additional thera-
peutic targets for eliminating CSCs.
IMMUNE CELL/CYTOKINES (MYELOID–DERIVED SUPPRESSOR
CELLS, IL–6, ETC.)
Myeloid-derived suppressor cells (MDSCs) represent a hetero-
geneous population including immature macrophages, DCs,
granulocytes, and other myeloid cells at earlier stages of differ-
entiation [78]. MDSCs can directly incorporate into tumor
endothelium and secrete many proangiogenic factors. They also
induce the production of matrix metalloproteinases, chemo
attractants, and create a premetastatic environment [78]. Panni
et al. demonstrated the role of MDSC in promoting the
ALDHhigh CSCs in pancreatic cancer in a mouse model [79].
STAT3 signaling in MDSCs can be modulated by IL-6, which has
been shown to enhance CSCs and EMT in cancer [80, 81]. Cui
et al. also reported that MDSCs enhance CSC gene expression,
sphere formation, and cancer metastasis in patients with ovar-
ian carcinoma [82]. To the best of our knowledge, there are no
published studies on targeting MDSCs for CSC elimination.
However, given the roles of MDSCs in tumor invasion and
metastasis, immunological targeting of MDSCs represents a
rational approach for targeting CSCs.
Recently, Korkaya et al. demonstrated that monocytes and
macrophages recruited to breast tumor directly regulate CSC
through inflammatory cytokines IL-1, IL-6, and IL-8 in the CSC
niche which are involved in driving CSC self-renewal [9]. These
cytokines activate STAT3/NF-ŒB pathways in both tumor and
stromal cells, which in turn stimulate further cytokine produc-
tion, generating positive feedback loops that contribute to
CSC self-renewal [10]. Inhibitors of these cytokines and their
receptors have been developed and trials to use these inhibi-
tors to block CSC self-renewal have been initiated [9, 83].
Immunologically, blockade of the IL-8 receptor CXCR1 using
antibody or repertaxin (a small-molecule CXCR1 inhibitor)
selectively depletes the CSC population in human breast can-
cer cell lines in vitro, followed by the induction of massive
apoptosis in the bulk tumor population via FASL/FAS signaling
[84]. In addition, IL-6 has been shown to be a direct regulator
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for CSC self-renewal [85–87]. Anti-IL-6 antibody inhibited JAK1
and STAT3 activation as well as OCT-4 gene expression, thus
inhibiting CSCs [88]. These studies suggest that IL-6R blockade
may provide attractive therapies in attempt to immunologi-
cally target CSCs.
Immune Checkpoints (PD-1/PD-L1)
Immune checkpoints are cell surface molecules that serve as
endogenous regulators of the immune response, limiting auto-
immunity by mediating coinhibitory signaling pathways [89].
In cancer, these inhibitory pathways are involved in tumor
immune-resistance [90]. To date, two major immunoinhibitory
pathways have been recognized, namely the programmed cell
death-1 (PD-1)/PD-L1 axis, and the CTL antigen 4 (CTLA-4)/B7
axis. These negative immune regulatory pathways have been
proposed to contribute to a suppressive microenvironment
that protects cancer cells from immune destruction [91, 92].
CSCs might reciprocally modulate the immune cells in CSC
niche through the secretion of paracrine factors or direct cell-
cell contact, based on the concept that physiologic stem cells
have immunoprivilege and active immunoregulatory functions
[93–97]. Schatton et al. reported evidence that CSCs downreg-
ulate T-cell activation [98, 99]. They identified a novel type of
CSCs, malignant melanoma-initiating cells (MMIC), based on
their expression of the chemoresistance determinant ABCB5
[98]. Tumorigenic human ABCB51 MMICs preferentially
express PD-1 and B7.2, while having downregulated expres-
sion of PD-L1 compared to ABCB52 cells. Recently PD-1 and
PD-L1 antibodies have been shown to have clinical benefit in
a variety of cancers including melanoma and lung cancer
[100, 101] and most recently in refractory Hodgkins disease
[102]. In these studies, a subset of patients enjoy prolonged
responses often considerably more durable that those pro-
duced by cytotoxic or even targeted therapies. It is postulated
that expression of PD-L1 on tumors may downregulate acti-
vated T-cell responses via the PD-L1/PD-1 axis; and its block-
ade results in effective T-cell responses. Although Schatton
et al. reported decreased PD-L1 expression on MMICs [99]; a
recent study demonstrated preferential expression of PD-L1
on CSC in head and neck carcinoma [103]. This opens the pos-
sibility that subsets of CSCs may downregulate T-cell immunity
via the PD-1/PD-L1 axis. Assessment of CSCs in future clinical
trials involving immune checkpoint blockade will be necessary
to determine whether this is the case. Furthermore, combina-
tion of immune checkpoint therapies with CSC targeting
immunotherapies such as vaccines may enhance the clinical
utility of each approach.
SUMMARY
Multiple immunotherapeutic approaches to target CSCs are in
development. As outlined in Figure 2, these include direct tar-
geting of CSCs with immunological methods, for example,
CSC-DC vaccine; blocking the “help” to CSCs from the tumor
microenvironment, for example, anti-IL-6 mAb, and inhibiting
CSC-mediated immune suppression, for example, blockade
with anti-PD-1/PD-L1 mAbs. It will be necessary to rigorously
test these strategies alone or in combination to determine
their therapeutic efficacy. However, immunologic targeting of
CSCs represents a promising new direction in cancer thera-
peutics which we postulate will be more effective as combina-
torial therapy with conventional modalities as well as with
immunomodulatory agents.
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